Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Axsome Thera (NQ: AXSM )

90.07 -0.63 (-0.69%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Thera

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
3 Stocks That Have Turned $50,000 Into More Than $500,000 in Just 5 Years
Is it too late to invest in these fast-growing stocks? 
Via The Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
The types of innovative drugs these companies develop are always in high demand. 
Via The Motley Fool
Prediction: These 3 Stocks Will Soar in 2024
Investors could enjoy an especially happy new year with these great stocks. 
Via The Motley Fool
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
3 Unstoppable Stocks to Buy Right Now
These stocks could be just the ticket for investors seeking strong growth. 
Via The Motley Fool
Analyst Expectations for Axsome Therapeutics's Future
Via Benzinga
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today
From Axsome Therapeutics, Inc.
Via GlobeNewswire
AXSM DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
From The Rosen Law Firm PA
Via GlobeNewswire
AXSM FINAL DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM
WHY: NEW YORK, NY - (NewMediaWire) - November 25, 2023 - Rosen Law Firm, a global investor rights law firm, reminds investors of the common stock of Axsome Therapeutics, Inc. (“Axsome”) (NASDAQ: AXSM)... 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
AXSM FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
From The Rosen Law Firm PA
Via GlobeNewswire
Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7
From Axsome Therapeutics, Inc.
Via GlobeNewswire
3 Biotech Stocks That Could Be Millionaire Makers
Many biotech stocks offer exciting long-term growth prospects. 
Via The Motley Fool
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
From The Rosen Law Firm PA
Via GlobeNewswire
Rosen Law Firm Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Axsome Therapeutics, Inc. and Certain Officers – AXSM
From The Rosen Law Firm, P.A.
Via Business Wire
3 Growth Stocks to Buy Right Now Without Any Hesitation
Investors shouldn't have to deliberate for too long about these great stocks. 
Via The Motley Fool
3 Healthcare Stocks That Have More Than Doubled in Value Since the Fed Started Raising Interest Rates
Can these promising growth stocks continue rising in value? 
Via The Motley Fool
Topics Economy
Exposures Interest Rates
Axsome's Strategy on Payer Coverage Slowly Pays Off, Depression Drug Sales Show Growth
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q3 revenues of $57.8 million, up 244% Y/Y, beating the consensus of $54.75 m 
Via Benzinga
Axsome Therapeutics (AXSM) Q3 2023 Earnings Call Transcript
AXSM earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023
Axsome’s headquarters to be lit in teal as part of the Alzheimer’s Foundation of America awareness campaign 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present at Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Riding the Wave: 3 Stocks That Can 10X by 2025
Are you looking to invest in stocks with the potential to 10x? Here are three stocks that can 10x by 2025. 
Via InvestorPlace
Got $2,000? Here Are 2 Beaten-Down Growth Stocks to Buy Right Now
Now, you can scoop up these future growth winners for a bargain. 
Via The Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Neither has performed well on the stock market this year. 
Via The Motley Fool
Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
3 No-Brainer Stocks to Buy Right Now for Less than $100
You can start with a small investment and win big over time. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.